Targeting telomerase.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Telomerase is constitutively expressed in most human tumors, making it a key therapeutic target.
• Telomerase inhibition strategies include targeting TERT, TERC, telomere DNA, or using combination therapies.
• Some immortalized cancer cells (10-15%) maintain telomeres via alternative lengthening of telomeres (ALT) in a telomerase-independent manner.

Purpose of the Study:

• To investigate the implications of telomerase inhibition as an anticancer strategy.
• To explore the potential for telomerase inhibition to select for cancer cells utilizing alternative lengthening of telomeres (ALT).

Main Methods:

• Review of current therapeutic strategies targeting telomerase.
• Analysis of cancer cell mechanisms for telomere maintenance, including telomerase-dependent and ALT pathways.
• Consideration of the impact of telomerase inhibition on the selection of ALT-positive cancer cells.

Main Results:

• Telomerase inhibition is a broad-spectrum therapeutic approach for many cancers.
• Alternative lengthening of telomeres (ALT) represents a resistance mechanism in a subset of cancer cells.
• The study highlights the critical need to understand the interplay between telomerase inhibition and ALT activation.

Conclusions:

• Telomerase inhibition is a viable anticancer strategy with various therapeutic approaches.
• The emergence of ALT-mediated telomere maintenance under telomerase inhibition pressure is a significant concern.
• Further research is crucial to determine if telomerase inhibition selects for ALT-dependent cancer cells, impacting treatment efficacy.